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Abstract
The incidence of Human Papillomavirus (HPV)-associated oropharyngeal squamous cell
carcinoma (OPSCC) is increasing rapidly in the UK. Patients with HPV-positive OPSCC
generally show superior clinical responses relative to HPV-negative patients. We hypothe-
sised that these superior responses could be associated with defective repair of DNA double
strand breaks (DSB). The study aimed to determine whether defective DNA repair could be
associated with sensitivity to inhibition of DNA repair using the PARP inhibitor Olaparib.
Sensitivity to Olaparib, and induction and repair of DNA damage, were assessed in a panel
of 8 OPSCC cell-lines, including 2 novel HPV-positive lines. Effects on cell cycle distribution
and levels of PARP1 and p53 were quantified. RNA-sequencing was used to assess differ-
ences in activity of DNA repair pathways. Two HPV-positive OPSCC lines were sensitive to
Olaparib at potentially therapeutic doses (0.1–0.5 μM). Two HPV-negative lines were sensi-
tive at an intermediate dose. Four other lines, derived from HPV-positive and HPV-negative
tumours, were resistant to PARP inhibition. Only one cell-line, UPCISCC90, showed results
consistent with the original hypothesis i.e. that in HPV-positive cells, treatment with Olaparib
would cause accumulation of DSB, resulting in cell cycle arrest. There was no evidence that
HPV-positive tumours exhibit defective repair of DSB. However, the data suggest that a sub-
set of OPSCC may be susceptible to PARP-inhibitor based therapy.
Background
Oropharyngeal Squamous Cell Carcinoma (OPSCC) develop in the tonsils, base of tongue,
pharyngeal wall and soft palate. These tumours have historically been associated with tobacco
and alcohol consumption, but in recent decades, many parts of the developed world have seen
a rapid and dramatic rise in incidence of OPSCC caused by Human Papillomavirus (HPV) [1–
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3]. Multiple studies have demonstrated that patients with HPV-positive OPSCC survive signif-
icantly longer than patients with HPV-negative disease, despite commonly presenting with
clinico-pathological features usually associated with poor prognosis (e.g. nodal metastases and
extracapsular spread) [4–7]. The increased duration of survival in HPV-positive OPSCC
means that patients may live for many years with the late side-effects of treatment, hence
reducing the toxicity of treatments has become a priority. This need can partly be addressed
through clinical trials which de-intensify treatment [8–10]. Reduced toxicity could also be
achieved through greater use of targeted HPV-specific therapies. However, preclinical assess-
ment of potential novel therapies is hampered by a lack of relevant in vitro models. HPV-posi-
tive OPSCC is a relatively new disease entity and only a few validated cell-lines derived from
treatment-naïve HPV-positive OPSCC, typically tonsil cancers, are available worldwide [11].
There are hence parallel needs for additional cell-lines models of HPV-positive OPSCC, and
for rationally targeted therapies to maintain good outcomes whilst reducing treatment-related
late toxicities.
It has been proposed that the better prognosis of HPV-positive OPSCC patients, relative to
HPV-negative patients, is partly attributable to greater intrinsic cellular radio-sensitivity
[11,12]. It is well established that in productive infections, in which the viral life cycle is com-
pleted and new virus particles are produced, HPV subverts components of the DNA damage
response, including ATM, ATR, FANCD2, BRCA1, to facilitate differentiation-dependent rep-
lication of its genome [13,14]. However, the relationship between the DNA damage response
and HPV in the context of non-productive infections, associated with carcinogenesis, is less
well defined. Several studies have suggested that expression of HPV oncogenes in tumour cells
is associated with defects in repair of DNA double strand breaks (DSB), possibly through
down regulation of DNA-PK and BRCA2 [15,16], potentially conferring a “BRCA-like” phe-
notype on HPV-infected cells. Given this possibility, we hypothesised that HPV-positive
OPSCC might be vulnerable to synthetic lethal therapy using PARP inhibition. Our model
proposed that inhibition of repair of DNA single strand breaks (SSB) would be followed by
conversion of SSB to DSB during replication, and cells with less effective repair of DSB, i.e. a
BRCA-like phenotype, would accumulate DSB, resulting in cell cycle arrest and possibly apo-
ptosis. Hence the current study aimed to derive and characterise novel cell-lines from HPV-
positive OPSCC, and use these and other validated cell-lines, to investigate the potential of a
synthetic lethal approach to treatment of OPSCC. Sensitivity to the PARP inhibitor Olaparib
and its effects on cell cycle and levels of DNA DSB, and p53 protein were assessed. This work
was undertaken with the aim of generating preclinical data to support targeted treatments for
HPV-positive disease.
Materials and methods
Patients, cell-lines and cell culture conditions
Primary oropharyngeal tumour biopsies were obtained from patients prior to treatment for
OPSCC at Cardiff and Vale University Health Board, from February 2013 to May 2014. The
study was conducted with NHS Research Ethics Committee approval: Research Ethics Com-
mittee for Wales 13/WA/0002. Written informed consent was obtained for use of all patient
samples. The study was performed in accordance with the Declaration of Helsinki. Culture
methods were based on those of Stanley et al. [17]; briefly, fresh biopsies transported immedi-
ately to the laboratory and coarsely minced then incubated with Glasgow Modified Eagles
Medium with 10% Fetal Bovine Serum, 10ng/ml Epidermal Growth Factor, 500 ng/ml Hydro-
cortisone, 0.1 nM Cholera toxin, and 1x Penicillin/Streptomycin (Sigma-Aldrich, Gillingham,
UK). Cultures were supplemented with 60 Gy irradiated 3T3 fibroblasts. All cell cultures were
Olaparib and HPV oropharyngeal cancer cell lines
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incubated at 37˚C in 5% CO2. HPV status was assessed by p16 immunohistochemistry on the
diagnostic biopsy, and HPV GP5/6 and E6 PCR on tumour DNA [5].
UMSCC4 (HPV-negative, tonsil SCC), UMSCC6 (HPV-negative, base of tongue SCC),
UMSCC19 (HPV-negative, base of tongue SCC), UMSCC74a (HPV-negative, base of tongue
SCC), UMSCC47 (HPV-positive, lateral tongue SCC) cell lines were all obtained from the lab-
oratory of Professor Thomas Carey (University of Michigan, USA) [18,19]. UPCISCC90
(HPV-positive, base of tongue SCC) was obtained from DSMZ (Braunschweig, Germany).
These lines were obtained in October 2013 and were grown in DMEM with 10% Fetal Bovine
Serum. The identities of these lines were confirmed by analysis of Short Tandem Repeat (STR)
loci.
Human Epithelial Keratinocytes (HEKn) were grown in EpiLife media supplemented with
1% Human Keratinocyte Growth Supplement (HGKS) (cells and media from Thermo Fisher
Scientific, Waltham, USA).
Nucleic extraction and analysis
DNA and RNA were extracted using QiaAMP DNA and RNA Mini Kits, according to the man-
ufacturer’s instructions (Qiagen, Hilden, Germany). p53 status was determined by bi-direc-
tional sequencing of exons 2 to 11 and alignment with p53 genomic sequence NC_000017.9
[20]. STR analysis was performed using the ABI AmpFISTR Identifiler kit according to the
manufacturer’s instructions (Life Technologies, Carlsbad, USA), followed by analysis on an ABI
3130xl Genetic Analyser (Thermo Fisher Scientific, Waltham, USA).
mRNA sequencing
RNA transcriptome sequencing was performed at the Beijing Genomics Institute (TruSeq
RNA-seq protocol using Illumina HiSeq2000 to generate 90 bp paired-end reads). Quality con-
trol was performed using FastQC (Babraham Bioinformatics: http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). Initial mapping against human reference hg19 and HPV16
reference NC_001526.2 genome was performed using TopHat (version 2.0.8b) [21]. Gene
expression level was determined using RPKM (Reads per Kilobase exon Model per million
mapped reads) values for exons and transcripts using the RefSeq gene model RefGene for hg19
and NC_001526.2.
Differentially Expressed Genes (DEG) were identified using edgeR analysis [22] on normal-
ized count data with the Benjamini–Hochberg FDR method to account for multiple testing
and false discovery [23]. A p value of<0.05 was interpreted as statistically significant. A list of
the top 500 DEGs were subjected to over-representation analysis against Gene Ontology anno-
tations using the GOseq method with FDR correction [24]. Paired-end reads mapping to both
hg19 and NC_001526.2 were used to identify HPV:human fusion transcripts and generate Cir-
cos plots [25].
Clonogenic survival assays
Cells were plated at low density (2500–12500 cells/plate depending on cell line) in 6cm diame-
ter TC dishes and incubated for 24 h. Media was then replaced with media containing Olab-
parib (AZD2281—Selleckchem, Munich, Germany) or vehicle alone; DMSO concentration
was standardised for all cultures at 0.1%. After 7 days the media was replaced with fresh media
without Olaparib. After a further 7 days, media was removed and the cells were stained with
crystal violet. Colonies containing more than 50 cells were counted– 50 cells is a standard
threshold that allows macroscopic counting of colonies [26]. All experiments were performed
in triplicate and repeated 3 times.
Olaparib and HPV oropharyngeal cancer cell lines
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Cell cycle and γ-H2AX
Cell cycle distribution and levels of γ-H2AX (to quantify DNA DSB) were determined in pre-
pared nuclei by flow cytometry using DAPI (Sigma-Aldrich, UK) and anti-γ-H2AX antibody
(clone JBW301) fluorescein isothiocyanate (FITC) conjugate (Merck-Millipore, Watford, UK;
catalogue 16-202A) using published methodology [27]. Briefly, nuclei were prepared in lysis
buffer containing 320mM Sucrose, 10mM TRIS-HCl pH8, 2.5mM MgCl2 and 0.5% Triton X-
100, then filtered through a 20 μm CellTrics filter (Sysmex, Milton Keynes, UK). Flow cytome-
try was performed using a BD FACSCanto II flow cytometer (BD Biosciences, New Jersey,
USA) with excitation at 405 and 488nm. Data analysis was performed using FlowJo software
(FlowJo LLC, Ashland, USA).
Western blot analysis
Cells at 40% confluence had standard media replaced with media including varying concentra-
tions of Olaparib. They were then incubated for a further 48hr. Protein lysates were then pre-
pared according to standard protocols using reagents from Sigma-Aldrich, St Louis USA. 20μg
of protein was separated by SDS-PAGE electrophoresis. Western blots were performed using
the following antibodies: p53 (rabbit) cat-9282; phospho-p53 (Ser15) (rabbit) cat-9284; PARP1
antibody (rabbit) cat-9542; β-Actin (13E5) antibody (rabbit) cat-4970 –all from Cell Signalling,
Danvers, USA; and goat polyclonal secondary to rabbit IgG adsorbed cat: ab97080 (Abcam,
Cambridge UK). Bands were visualised using the ECL Prime Chemiluminescence system (GE
Healthcare, Chicago USA). Image capture was performed using a LAS-3000 imager (Fujifilm)
using an initial 30 s exposure then 2 min increments. Quantification was performed using
Image Studio Lite software (LI-COR Biotechnology, Cambridge, UK).
Results
Derivation of novel HPV-positive OPC cell-lines
Explant culture was attempted using fresh primary tumour biopsies from 12 patients with sus-
pected OPSCC. Eight biopsies produced explants but did not proliferate beyond a few pas-
sages; two biopsies did not produce explants. Two novel cell lines, CUOP2 and CUOP3, were
generated from the two biopsies in which sustained proliferation was achieved. These lines
have now been grown to approximately 100 and 80 population doublings respectively and
appear to be immortal. CUOP2 was derived from a p16-positive (>70% diffuse staining)
T4aN2bM0 tonsil tumour in a male, 52-year-old, never smoker. CUOP3 was derived from a
p16-positive T1N2aM0 tonsil tumour in a male, 44-year-old, ex-smoker with less than 10
pack/year history (Table 1). DNA and mRNA sequence data indicated the presence of HPV16
Table 1. CUOP2 and CUOP3 patient characteristics.
Study
number
Sex Age
(yrs)
Smoking statusa Site TNM Stage p16 IHC P53
status
HPV
type
Treatmentb Recurrencec
CUOP2 M 52 Never smoker Left tonsil T4aN2bM0 Positive Wt 16 ChemoRT None
CUOP3 M 44 Ex-smoker,
<10pack/yr
Right
tonsil
T1N2aM0 Positive Wt 16 Transoral laser resection, neck dissection,
post-op RT,
None
a Pack-years refers to the number of cigarette packs smoked per day multiplied by the number of years the person has smoked.
b Radiotherapy (RT), post-operative (post-op).
c Recurrence as reported in September 2017.
https://doi.org/10.1371/journal.pone.0207934.t001
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and wild-type p53 in both lines. DNA fingerprinting, using Short Tandem Repeat analysis,
confirmed that the cell-lines were derived from the original patient biopsies. Both lines tested
negative for mycoplasma and expression of p16 was confirmed by immunohistochemistry
(S1 Fig).
Transcriptomic analysis indicates similar DNA repair activity in HPV-
positive and negative cell lines
Paired-end mRNA sequencing was performed in our two novel HPV-positive cell-lines,
CUOP2 and CUOP3, and in the two HPV-positive cell lines acquired from other laboratories,
UMSCC47 and UPCISCC90, to assess the pattern of expression of HPV encoded genes (Fig
1), and determine whether fusion transcripts, arising from integrated viral DNA, were present
(Fig 2). This analysis showed the highest levels of expression of HPV16 encoded oncogenes in
Fig 1. Quantification of HPV transcription. mRNA levels of HPV encoded genes were quantified in HPV-positive
OPSCC cell lines. Reads Per Kilobase of transcript per million Mapped reads (RPKM) are plotted for the individual
HPV open reading frames (ORF) of the four HPV-positive cell lines.
https://doi.org/10.1371/journal.pone.0207934.g001
Olaparib and HPV oropharyngeal cancer cell lines
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the UMSCC90 and CUOP3 cell-lines. Fusion transcripts were identified in all four HPV-posi-
tive cell-lines indicating the presence of integrated virus (S1 Table), however the presence in
several lines, especially CUOP2 and CUOP3, of transcripts encoded downstream of E6 and E7
suggests presence of full length HPV genomes either in integrated or episomal form.
Fig 2. Determination of HPV integration state. Circos plots were used to illustrate fusion transcripts between HPV16 and human genome. HPV16 sequences
and human chromosomes are not to scale. Fusion transcripts are represented as grey lines indicating where read ends mapped. Thicker/darker lines indicate
multiple reads detected.
https://doi.org/10.1371/journal.pone.0207934.g002
Olaparib and HPV oropharyngeal cancer cell lines
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mRNA-seq was also performed on the HPV-negative lines. The combined datasets were
used to investigate differences in gene expression between HPV-positive and negative lines,
and specifically to determine whether there were differences in expression of genes involved in
repair of DNA DSB or SSB/base damage. After correction for multiple testing (Benjamini–
Hochberg FDR p<0.05), 211 transcripts were significantly differentially expressed between
HPV-positive and negative lines (Fig 3). These differences were investigated further using
Gene Ontology Over Representation Analysis (GO-ORA). The differentially expressed genes
were predominantly related to metabolic processes including glucoronidation, flavonoid and
uronic acid metabolism. Several cellular processes including extracellular matrix (ECM) orga-
nisation and chromosome organisation were also significantly differentially regulated (see S2–
S4 Tables for a full list of significant ontologies). Ontology directed heatmaps were generated
for DSB repair, Base Excision Repair (BER), APOBEC activity, and p53-mediated signalling in
response to DNA damage, but these analyses did not suggest any consistent and/or significant
differences, between HPV-positive and negative cells (S2 Fig–S5 Fig).
In consideration of their potential relevance to HPV status and DNA repair, transcript lev-
els of several individual genes of interest were assessed (Fig 4). This demonstrated trends for
greater abundance of transcripts for p53 and p16 in the HPV positive lines, but no differences
in the levels of p21 or PARP1. In the HPV-positive UPCISCC90 cell-line, levels of PARP1
were 2–3 fold higher than in any other line, while the HPV-negative line UMSCC19 showed
the second highest levels of PARP1 transcripts. Levels of PARP1 protein were also assessed by
western blot, which also showed highest levels of PARP1 in UPCISCC90 and UMSCC19
(Fig 5).
Response to Olaparib does not correlate with HPV status
To determine whether sensitivity to the PARP inhibitor Olaparib correlated with HPV status,
response to Olaparib was assessed at a range of concentrations (0.1–10 μM) using colony for-
mation assays (Fig 6). All lines were sensitive to high doses of Olaparib (10 μM), which caused
a reduction in colony formation of nearly 100% in 5 out of 8 lines. However, at doses between
0.5–1 μM, the surviving fractions differed significantly between lines (ANOVA p<0.001). In
this dose range, three groups were apparent: a sensitive group defined as SF<40%, including
two HPV-positive lines (UPCISCC90 and CUOP2), a medium sensitivity group with SF 40–
80%, comprising an HPV-negative line and normal human epidermal keratinocytes
(UMSCC74a and HEKn) and a resistant group with SF>80%, including 2 HPV-positive and 2
HPV-negative lines (UMSCC19, 4, 47 and CUOP3). This is only partially consistent with
hypothesis that HPV status would correlate with response to Olaparib. It was also apparent
that pre-treatment levels of PARP1 did not correlate with sensitivity to Olaparib, as the two
lines with highest expression of PARP1, UPCISCC90 and UMSCC19, were in the sensitive and
resistant groups respectively.
Accumulation of DSB does not correlate with Olaparib sensitivity or HPV
status
Phosphorylation at the Ser-139 residue of the minor histone H2AX (termed γ-H2AX), signals
and initiates repair of DSB, and is a key step in the DNA damage response. Detection of this
phosphorylation event provides a specific and sensitive molecular marker for DNA damage,
allowing assessment of initial damage and its subsequent resolution [28]. Levels of histone γ-
H2AX were assessed at 24 and 48 hrs following Olaparib treatment (Fig 7). All OPSCC lines
except UMSCC47 showed significantly increased levels of γ-H2AX 24 hrs following Olaparib
treatment. In two of the HPV-positive lines, CUOP2 and 3, these levels returned to normal
Olaparib and HPV oropharyngeal cancer cell lines
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Fig 3. Gene expression in HPV positive and negative cell lines. The heatmap represents differential gene expression
between HPV-positive and negative cell lines. Gene expression was normalised across the dataset: black represents the
median, green represents expression below the median and red above median. After correction for multiple testing,
211 transcripts were significantly differentially expressed between the two groups (Benjamini–Hochberg FDR p<0.05).
https://doi.org/10.1371/journal.pone.0207934.g003
Olaparib and HPV oropharyngeal cancer cell lines
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within 48 hrs, suggesting competent repair of DSB in these lines. For the two lines that were
most sensitive to Olaparib, one showed competent repair (CUOP2) while the other
(UPCISCC90) showed a marked inability to repair DSB; hence, sensitivity to Olaparib, did not
Fig 4. mRNA levels of p53, p21, p16 and PARP1 in HPV positive and negative cell lines. The number of reads,
expressed as RPKM, for p53, p21, p16 and PARP1 was determined. Data are depicted as histograms with tabulated
values showing fold change between the HPV-positive and negative groups, and significance by T-test with and
without fdr adjustment for multiple tests.
https://doi.org/10.1371/journal.pone.0207934.g004
Olaparib and HPV oropharyngeal cancer cell lines
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appear to correlate with accumulation of DSB. Similarly, HPV-positive cells did not show
impaired resolution of DSB relative to HPV-negative lines. In fact, the opposite trend was
apparent; forty-eight hours after 10 μM Olaparib treatment, increased levels of γ-H2AX were
evident in 2/4 HPV-positive lines and 3/3 HPV-negative OPSCC lines.
Fig 5. PARP1 protein in HPV-positive and negative cell lines. Protein was extracted from untreated cells and probed
for PARP1 and β-actin (loading control). Image analysis was used to estimate relative levels of PARP1, and showed
expression at>3-fold above the group median in UPCISCC90, and at>2-fold above the median in UMSCC19.
https://doi.org/10.1371/journal.pone.0207934.g005
Fig 6. Surviving fractions of OPSCC cell lines in response to Olaparib treatment. Panel A: HPV-positive cells. At all doses between 0.1 & 10 μM Olaparib,
PCOC2 and UPCISCC90 showed significantly lower surviving fractions compared to PCOC3 and UMSCC47 (p<0.05; two way ANOVA with Bonferroni post-test).
Panel B: HPV-negative cells. At doses of 0.5 & 1 μM Olaparib, HEKn and UMSCC74a showed significantly lower surviving fractions compared to UMSCC19 and
UMSCC4 (p<0.05; two way ANOVA with Bonferroni post-test). The results are representative of at least 3 experiments, all performed in triplicate. Mean and
standard deviation are shown.
https://doi.org/10.1371/journal.pone.0207934.g006
Olaparib and HPV oropharyngeal cancer cell lines
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Cell cycle arrest following Olaparib treatment partially correlates with
sensitivity to Olaparib
The effects of Olaparib treatment on cell cycle distribution were assessed using flow cytometry
(Fig 8). After 24 hrs, a correlation with sensitivity to Olaparib was apparent, with the two sensi-
tive lines, CUOP2 and UPCISCC90, showing significant accumulation in G2 and S phase
respectively. After 48 hrs, an increased G2 fraction was no longer evident in CUOP2, whereas
UPCISCC90 displayed significant accumulation of cells in G2. For the cells that showed inter-
mediate sensitivity to Olaparib, HEKn and UMSCC74a, HEKn showed a significant increase
in cells in G2 at 24 hrs, and a non-significant increase at 48 hrs, while UMSCC74 showed non-
significant increases in G2 fraction at both time-points. UMSCC47 showed significant expan-
sion of the G2 fraction after 48 hrs. Overall, there seemed to be a general trend for accumula-
tion of cells in G2 following Olaparib treatment, with the greatest effect visible in the most
sensitive line (UPCISCC90).
Fig 7. Induction of γ-H2AX following Olaparib treatment. Induction of γ-H2AX foci was assessed 24 & 48 hrs after treatment with 10 μM Olaparib.
γ-H2AX levels were quantified using flow cytometry and are depicted as Mean Fluorescent Intensity (MFI) normalised to vehicle for each cell line.
Data are representative of at least 3 independent experiments (ANOVA and Tukey post test, � P< 0.05, �� P<0.01, ��� P<0.001). Error bars indicate
standard deviation. Baseline levels of γ-H2AX in untreated cells are shown in S6 Fig.
https://doi.org/10.1371/journal.pone.0207934.g007
Olaparib and HPV oropharyngeal cancer cell lines
PLOS ONE | https://doi.org/10.1371/journal.pone.0207934 December 13, 2018 11 / 18
Accumulation of DSB and G2 arrest are not associated with apoptosis in
HPV-positive cell-lines
It has been suggested that the superior response to therapy observed in patients with HPV-pos-
itive OPSCC may arise from an incomplete p53 phenotype arising from proteosomal degrada-
tion of p53, relative to the more complete phenotype conferred by mutation. According to this
hypothesis residual low levels of p53 activity could promote an apoptotic response. To deter-
mine whether p53 mediated responses and apoptosis are relevant in the response to Olaparib,
protein levels of p53, phosphorylated p53, and cleaved caspase were assessed (caspase mediated
cleavage of PARP1 provides a sensitive and specific marker for apoptosis [29]) (Fig 9). Cells
irradiated at a dose of 10 Gy were included to investigate whether a p53 mediated response
could be detected in response to an alternative stimulus.
UMSCC74a was the only line that showed accumulation of p53 and phospho-p53, at 24 and
48 hrs, in response to 10 μM Olaparib (Fig 9), but this did not result in apoptosis, as assessed
by cleavage of PARP1. Similarly, there was no microscopic evidence for apoptosis e.g. blebbing
Fig 8. Cell cycle distribution following Olaparib treatment. The proportion of cells in G1, S and G2 for HPV-positive and negative cell lines 24 & 48 hrs
post treatment with vehicle and 10 μM Olaparib are shown. Data are representative of at least 3 independent experiments (ANOVA and Tukey post test, �
P< 0.05, �� P<0.01, ��� P<0.001). Error bars indicate standard deviation.
https://doi.org/10.1371/journal.pone.0207934.g008
Olaparib and HPV oropharyngeal cancer cell lines
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or cell shrinkage. p53 and phospho-p53 were also induced by Ionising Radiation (IR) in
UMSCC74a cells. CUOP2 showed evidence of apoptosis, as indicated by cleaved PARP1, in
response to IR, but not Olaparib. Conversely, HEKn cells displayed accumulation of p53 and
phospho-p53 following IR, but no PARP1 cleavage indicating apoptosis. It was notable that
even in UPCISCC90, substantial G2 arrest following 10 μM Olaparib was not associated with
stabilisation and activation of p53 or apoptosis. Similarly, IR did not cause a detectable p53 or
apoptotic response in this line. In summary, Olaparib treatment resulted in accumulation/acti-
vation of p53 in just one of the eight lines, and was associated with apoptosis in none of them.
Discussion
Two novel cell-lines, CUOP2 and 3, were derived from HPV16-positive tonsil cancers from
patients who are typical of the demographic increasingly affected by this disease i.e. both
patients were relatively young, male, and with no or a low-level history of tobacco consump-
tion. The molecular characteristics of the lines are also typical of HPV-positive tumours; both
CUOP2 and 3 are p16-positive with wild-type p53. mRNA sequencing was used to demon-
strate active transcription of the HPV16 E6 and E7 oncogenes. These lines were included in a
panel of OPSCC cell-lines which was used to assess the effects of Olaparib treatment.
Fig 9. Protein levels of PARP1, cleaved PARP1, p53 and phospho-p53 48hrs following Olaparib treatment. Results for untreated and Olaparib dosed cells are
shown. Cell lines treated with 10Gy ionising radiation, collected 24hrs post irradiation, were also included. Two membranes were used: one for PARP1 and cleaved
PARP1 and β-actin 1; and the other for p53 and β-Actin 2.
https://doi.org/10.1371/journal.pone.0207934.g009
Olaparib and HPV oropharyngeal cancer cell lines
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We had hypothesised that suboptimal repair of DSB in HPV-positive cells would confer
sensitivity to PARP inhibition, and this would be associated with accumulation of DSB and G2
phase arrest. We also considered the possibility that an incomplete p53-negative phenotype
would be associated with apoptosis following G2 arrest. We observed however, that sensitivity
to Olaparib showed only partial correlation with HPV status: two of the four HPV-positive
lines were classed as sensitive while two were classed as not sensitive to Olaparib.
There was no evidence to suggest less effective repair of DSB in HPV positive cells, in fact,
the data seem to suggest the opposite. Three of the HPV-positive lines showed significantly
increased levels of γ-H2AX 24 hrs after treatment with 10 μM Olaparib, but in two of these
lines, levels had returned to baseline by 48 hrs, suggesting that the DSB had been repaired. In
contrast, all of the HPV-negative OPSCC lines showed significantly increased levels of γ-
H2AX at 24 hrs that were not repaired at 48 hrs. There was no evidence to support accumula-
tion and activation of p53 in HPV-positive lines in response to Olaparib, or IR alone. Further-
more, the mRNA sequencing data did not indicate presence of functional p53 or any
constitutive induction of DNA repair mechanisms in HPV-positive cells.
There is very little existing published in vitro data on the effects of PARP inhibition in
OPSCC. In a study comparing response to 2–10 μM Veliparib in two HPV-positive vs one
HPV-negative HNSCC cell-lines (UMSCC47, UPCISCC154 and UMSCC1 respectively), the
HPV-negative line appeared approximately 1.5 fold less sensitive, and, contrary to our study,
slower resolution of γ-H2AX foci in the HPV-positive cell-lines was observed [16]. A second
study assessed the effects of Olaparib in four of the lines used in the current study (UMSCC
47, 6, 74a and UPCISCC90) but reported Olaparib, at doses up to 1 μM, as having no effect on
cell proliferation, as determined using clonogenic assays, in any line, although this may be
related to a shorter exposure to Olaparib (24 hrs versus the 7 days used in the current study)
[15]. In a study by Wurster et al. the effects of 1 μM Olaparib were investigated in a panel of 10
HPV-negative HNSCC cell-lines [30]. These lines had been classified as homologous repair
proficient or deficient, but none showed a substantial response to Olaparib, defined as>20%
reduction in SF in clonogenic assays at 14 days. This suggests that DNA repair capacity is not
predictive of response to Olaparib as monotherapy, but also that most HPV-negative HNSCC
cell-lines may be resistant to Olaparib at dose levels at which some HPV-positive lines may be
sensitive. It is hence possible that UMSCC74a may be unusual in showing “intermediate” sen-
sitivity to Olaparib.
Whether p53 accumulates and causes apoptosis in HPV-positive HNSCC lines is controver-
sial. One previous study reported accumulation of p53, caspase activation and increased
annexin V binding in HPV-positive cells following 4 Gy IR [12]. However, a similar study
reported no accumulation of p53 and the absence of caspase activation and PARP1 cleavage
[11]. It should be noted however that the 15 HNSCC lines assessed represented a very diverse
group that was not representative of typical HPV-positive oropharyngeal cancers, and only
three lines were included in both studies. The relevance of these observations in the context of
Olaparib monotherapy is uncertain, but accumulation of p53 and apoptosis were not provoked
in response to the dosing regimen used in the current study.
UPCISCC90 and CUOP2 were sensitive to Olaparib at potentially therapeutic levels, how-
ever the mechanism for this effect appeared to differ between the two lines. In UPCISCC90
Olaparib sensitivity may be attributable to delayed resolution of DSB, as suggested by
increased levels of γ-H2AX at 24 and 48 hrs, resulting in prolonged G2 arrest; alternatively, the
high pre-treatment levels of PARP1 might indicate constitutive induction and reliance on the
BER pathway. This is consistent with the observation that PARP is hyperactivated in cells with
BRCA2 mutations and other defects in repair of DSB by homologous recombination [31].
APOBEC activity is induced in HPV-positive HNSCC [32], and this could result in
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upregulation of pathways contributing to repair of U:G mismatches, including BER [33]. How-
ever, this appears unlikely in the case of UPCISCC90, as there was no evidence of significant
upregulation of APOBEC or BER pathway genes in the mRNA-seq data. The CUOP2 line
showed competent repair of DSB with a transient G2 arrest, evident at 24 but not 48 hrs, and
no evidence of apoptosis. The line also showed average levels of baseline PARP1. It is hence
difficult to speculate as to the mechanism underlying the line’s highly significant sensitivity to
Olaparib.
It is highly likely that the effects of HPV, in terms of response to therapy, will be dependent
on the cell of origin [12]. This highlights the importance of using cellular models that best
reflect the disease under investigation. This has been achieved in the current study by deriva-
tion of new cell-lines and use of exclusively oropharyngeal models. It is notable that due to the
scarcity of treatment-naive OPSCC cell-lines, many previous studies have used HNSCC lines
with diverse aetiologies and then drawn inferences regarding HPV-positive and negative
OPSCC. We do however acknowledge that our study is based on only 8 cell-lines. There
remains an urgent need for additional OPSCC cell-lines that represent the emerging demo-
graphic group.
Our findings suggest that some HPV-positive OPSCC cells may be sensitive to Olaparib at
dose levels that may make monotherapy viable. This does not appear to be generally true of
their HPV-negative counterparts. Only the results for UPCISCC90 were consistent with the
original hypothesis, i.e. that in HPV-positive cells, treatment with Olaparib would cause accu-
mulation of DSB, resulting in cell cycle arrest. For the other cell-lines, the data were more com-
plex. The diverse responses across the cell-line panel suggests that caution should be exercised
with regard to conclusions drawn in studies including only a small number of cell-lines. We
did not observe any evidence to support an HPV-associated defect in repair of DSB, and our
data are more consistent with the improved prognosis of HPV-positive OPSCC patients being
associated with immune responses [34], than to defects in DNA repair or activation of
p53-mediated apoptosis. This is also consistent with better patient outcomes being reported in
HPV-positive patients who were treated surgically, as well as in those treated with chemo-
radiotherapy [5,35–37]. Elucidation of the mechanisms responsible for sensitivity to Olaparib
remains important, as this may allow identification of predictive markers to allow targeting of
this treatment to patients in whom it will be effective. Without a predictive marker, our pre-
clinical data suggest that monotherapy with Olaparib would not be effective in the majority of
patients.
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